NCT06609200

Brief Summary

This clinical trial aims to evaluate the efficacy and safety of electro-acupuncture for obese patients with insulin resistance. 60 participants will be randomized and allocated to either the electro-acupuncture arm or the sham acupuncture arm.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable obesity

Timeline
5mo left

Started Oct 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress79%
Oct 2024Oct 2026

First Submitted

Initial submission to the registry

September 20, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 24, 2024

Completed
16 days until next milestone

Study Start

First participant enrolled

October 10, 2024

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 9, 2026

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 9, 2026

Expected
Last Updated

April 9, 2026

Status Verified

April 1, 2026

Enrollment Period

1.5 years

First QC Date

September 20, 2024

Last Update Submit

April 6, 2026

Conditions

Keywords

electroacupunctureobesityinsulin resistance

Outcome Measures

Primary Outcomes (1)

  • delta HOMA-IR

    delta HOMA-IR = (end-of-treatment fasting insulin (ųU/mL)\* end-of-treatment fasting glucose (mmol/L)/22.5) - (baseline fasting insulin (ųU/mL)\* baseline fasting glucose (mmol/L)/22.5)

    From baseline to the end of treatment at week 8

Secondary Outcomes (2)

  • Body Mass Index (BMI)

    From enrollment to the end of follow-up at week 16

  • Waist-to-hip ratio

    From baseline to the end of follow-up at week 16

Study Arms (2)

Electroacupuncture group

EXPERIMENTAL

The WHO Standardized Acupuncture Points Location \[2\] will be used to identify the location of these acupoints, Tianshu(ST-25), Daheng(SP-15), Daimai(GB-24), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), and Sanyinjiao(SP-6). After sterilizing the skin, sterile adhesive pads will be pasted on acupoints first, and then needles of size 0.30\*75 mm will be inserted into the acupoints to a depth of 50 mm outward and upward slightly. Needles will be lifted, thrust, and twirled evenly 3 times to achieve "de-qi". Paired electrodes of the EA apparatus will be attached transversely to the acupoint respectively with a continuous wave of 50 Hz and a current intensity of 1-5 mA (preferably with the skin around the acupoints shivering mildly without pain) for 30 min. Patients will be treated with electroacupuncture 2 sessions per week over 8 consecutive weeks, 16 sessions for each patient.

Device: Acupuncture needles

Sham acupuncture group

SHAM COMPARATOR

The sham electro-acupuncture group (SEA) penetrates acupuncture on non-acupuncture points (1 cm away from the acupuncture point and meridian). The same type of acupuncture needles will be used for SEA with the exact skin sterilization method. All acupuncture points will be needled perpendicularly with a guide tube. Insertion depth will be approximately 50 mm, depending on the location of individual points. Each point will be connected to a sham electro-stimulator (showing a continuous wave at a frequency of 30 Hz but without actual stimulation). All needles will be removed after 30 min of needle retention. Patients will be treated with sham electroacupuncture 2 sessions per week over 8 consecutive weeks, 16 sessions for each patient in total.

Device: Acupuncture needles

Interventions

The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.

Electroacupuncture groupSham acupuncture group

Eligibility Criteria

Age21 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men and women aged between 21 and 65 years old
  • BMI ≥ 25 kg/m2
  • HOMA-IR ≥ 2.14, (HOMA-IR = fasting insulin (ųU/mL)\* fasting glucose (mmol/L)/22.5)
  • Not receiving any other weight control measures or any medical and/or drug history in the last 3 months

You may not qualify if:

  • Diabetes mellitus
  • Treating with drugs that may affect insulin sensitivity
  • Changes 10% of usual body weight in the previous 6 months weight
  • Endocrine diseases, including thyroid disorder, pituitary disorder, sex gland disorder, etc.
  • Heart diseases, including arrhythmia, heart failure, and myocardial infarction, participants with pacemakers
  • Allergy and immunology diseases
  • Bleeding tendency
  • Pregnant or lactating women
  • Impaired hepatic or renal function
  • Stroke or unable to exercise

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nanyang Technological University Traditional Chinese Medicine Clinic

Singapore, 637551, Singapore

RECRUITING

MeSH Terms

Conditions

ObesityInsulin Resistance

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsHyperinsulinismGlucose Metabolism DisordersMetabolic Diseases

Study Officials

  • Linda Zhong, Ph.D.

    nanyang technological university traditional chinese medicine clinic

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Linda Zhong, Assoc prof

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
After a participant's eligibility is confirmed, a randomization number that corresponds to the group allocation will be provided to the acupuncturist. The clinical assessor and participants will be blinded to the allocation.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Each patient will be scheduled for 16 treatment sessions, each lasting 30 minutes, twice a week over 8 weeks.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assoc prof

Study Record Dates

First Submitted

September 20, 2024

First Posted

September 24, 2024

Study Start

October 10, 2024

Primary Completion

April 9, 2026

Study Completion (Estimated)

October 9, 2026

Last Updated

April 9, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will share

IPD sharing will be available upon request.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
Data will become available within 7 years after completion of the clinical trial.
Access Criteria
Individual participant data (IPD) will be made available to qualified researchers upon request. To access the data, researchers must submit a formal request, which will be reviewed and approved by the data-sharing committee. Data access will be granted for research purposes only and will require adherence to data use agreements and ethics guidelines.

Locations